Neogenomics (NEO) Asset Writedowns and Impairment (2010 - 2025)

Neogenomics has reported Asset Writedowns and Impairment for 12 years, with the latest figure at $7.1 million in Q3 2025.

• For the quarter ending Q3 2025, Asset Writedowns and Impairment changed N/A year-over-year to $7.1 million; the trailing twelve-month figure through Dec 2025 stood at $15.3 million (up 2269.92% YoY), and the FY2024 full-year result was $500000.0, down 70.59% from the prior year.
• Asset Writedowns and Impairment for Q3 2025 stood at $7.1 million, down from $8.2 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $8.2 million in Q2 2025, with the low at -$3000.0 in Q4 2023.
• Historically, Asset Writedowns and Impairment has averaged $2.0 million across 4 years, with a median of $718000.0 in 2022.
• Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment sank 100.42% — and 2024, when it surged 16766.67%.
• Neogenomics' Asset Writedowns and Impairment stood at $718000.0 in 2022, then slumped by 100.42% to -$3000.0 in 2023, then surged by 16766.67% to $500000.0 in 2024, then surged by 1317.2% to $7.1 million in 2025.
• The last three Asset Writedowns and Impairment figures came in at $7.1 million (Q3 2025), $8.2 million (Q2 2025), and $500000.0 (Q4 2024), per Business Quant data.